Advanced Search:
Equity Index Forex Crypto Commodity

BIIB - Biogen

$198.18  -5.5 (-2.7%)

Updated: 03:08 May 5, 2024 EST

Next Hour's AI Forecast

99.58%

Avg. Accuracy (AI)

$219.52

Next Session's AI Forecast

93.79%

Avg. Accuracy (AI)

$205.93

Next Week's AI Forecast

83.33%

Trend's Accuracy (AI)

$204.07

Biogen's Position Within the Drug Manufacturers - General Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

BIOGEN - HISTORICAL DATA 6M

  • Last price

    $ 198.18

  • Daily change

    $ -5.5

  • Previous Close

    $ 203.68

  • Last Updated

    03:08 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.84 0.3 -0.12 -0 -0.14

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.6 1.55 1.35 1.21 1.11

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
36.06% 80.03% 91.91% 52.38%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
220.02 4.46% 210.63 1.44% 207.64 -9.94% 230.55

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.33 47.64 4.08 24.81

Biogen Technical Analysis News

Biogen

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Sectors: Healthcare
Industry: Drug Manufacturers - General
F. Time Employees: 7570
Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 2; Compensation: 9.

BIOGEN'S HOLDERS RANK

List of holders with stock participation in Biogen.

Holder Rank Holder Shares Date Reported % Out Value